Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson buys women's health-focused Uteron for up to $305m as it adopts Actavis name

This article was originally published in Scrip

Executive Summary

On the eve of Watson Pharmaceuticals' transition to a new name in honor of the company's $5.6 billion acquisition of global generics competitor Actavis in 2012, the US firm has announced a purchase worth up to $305 million that's meant to fill its brand-name drug pipeline and increase the company's presence in the women's health market.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts